Track accepted paper

CiteScore: 4.06ℹ
CiteScore measures the average citations received per document published in this title. CiteScore values are based on citation counts in a given year (e.g. 2015) to documents published in three previous calendar years (e.g. 2012 – 14), divided by the number of documents in these three previous years (e.g. 2012 – 14).

Impact Factor: 3.862ℹImpact Factor:2017: 3.862The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.
2017 Journal Citation Reports (Clarivate Analytics, 2018)

5-Year Impact Factor: 4.229ℹFive-Year Impact Factor:2017: 4.229To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years.
2017 Journal Citation Reports (Clarivate Analytics, 2018)

Source Normalized Impact per Paper (SNIP): 1.270ℹSource Normalized Impact per Paper (SNIP):2017: 1.270SNIP measures contextual citation impact by weighting citations based on the total number of citations in a subject field.

SCImago Journal Rank (SJR): 1.172ℹSCImago Journal Rank (SJR):2017: 1.172SJR is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and a qualitative measure of the journal’s impact.

Author StatsℹAuthor Stats:Publishing your article with us has many benefits, such as having access to a personal dashboard: citation and usage data on your publications in one place. This free service is available to anyone who has published and whose publication is in Scopus.

Q. Wang

Dr. Wang currently serves as a professor of chemical engineering at Iowa State University. He got his Ph.D. in Chemical and Petroleum Engineering from University of Kansas in 2010. He obtained another Ph.D. in Environmental Science and Engineering from Wuhan University in 2007. Before he joined Iowa State University in 2012, he has worked as Jorge Heller Postdoctoral Fellow at Harvard-MIT Division of Health Sciences and Technology of MIT and Harvard Medical School. Dr. Wang has worked as engineer in a chemical company and a pharmaceutical company before.

Dr. Wang’s areas of interest include Biomaterials, Intestinal Tissue Engineering, Nanotechnology, and Drug Delivery. In Iowa State University, Dr. Wang BINDs his research in these areas to produce innovative solutions and products for improving human health. Specifically, the current research in the Wang Laboratory focuses on intestinal engineering based on intestinal stem cells, stem cells reprogramming, and cell-mediated drug delivery. The intestinal stem cells can contribute to the diagnosis，treatment, and prevention of gastrointestinal tract related diseases, such as antimicrobial resistance, inflammatory bowel disease, diabetes, obesity, intestinal infection, and colorectal cancer. Moreover, discovery of substrates, pathways and growth factors involved in the differentiation of intestinal stem cells into specific lineages is expected to contribute significantly to the clinical protocols. The multidisciplinary research background enables Wang Lab to accomplish these goals. The ongoing projects include investigation of ex vivo culture systems of intestinal stem cells, development of new administration systems of intestinal stem cells, intestinal stem cells reprogramming, and oral drug delivery systems targeting to intestinal mucosa. Dr. Wang has successfully administered the projects, collaborated with other researchers, and produced several peer-reviewed publications from each project as documented in the peer reviewed journals. He has 64 peer-reviewed manuscripts in high impact scientific journals, including Advanced Materials, Advanced Drug Delivery Reviews, Biomaterials, Biotechnology Advances, Nanoscale, and Journal of Controlled Release. Importantly, 42 articles and books have been published since he joined Iowa State University. Notably, Dr. Wang is the corresponding senior author or first author in 45 of these highly influential papers. He has 9 invited scientific lectures and presentations from different research institutes. He has 11 contributed lectures and presentations at premier meetings of professional societies, including the Controlled Release Society, the American Association of Pharmaceutical Scientists, and the Society for Biomaterials. Dr. Wang has 7 major awards from scientific societies and professional organizations. Moreover, 11 peer-reviewed conferences proceedings or abstracts have been accepted for presentations. His inventions have led to a series of patents in the U.S. and China. Dr. Wang’s work has been frequently recognized and cited by other researchers from around the world. His personal H-index is 34, I10-index is 48, and the total citation is over 3,100 (Google Scholar).

As a measure of Dr. Wang’s impactful work in the fields of chemical and biomedical engineering, he has received numerous prestigious awards including the first Lloyd Mayer Scholar (CCFA), McGee-Wagner Interdisciplinary Research Award (ISU), PhRMA Foundation Research Starter Award, and Crohn’s & Colitis Foundation of America (CCFA) Career Award. These awards clearly recognize his significant contributions to improve the quality of life for humans afflicted with chronic, debilitating diseases. Dr. Wang’s reputation is also recognized by various academic societies as he serves as Editor, Associated Editor and Editorial Board members for prominent scientific journals. For example, he is the Editor of Royal Society of Chemistry (RSC) Smart Materials Series. He has served as Associate Editor of Journal of Biomedical Nanotechnology (Impact Factor: 4.521 in 2016; 3.929 in 2015; 5.338 in 2014; 7.578 in 2013) and is an Editorial Board Member of the International Journal of Pharmaceutics (Impact Factor: 3.649 in 2016; 3.994 in 2015; 3.650 in 2014; 3.785 in 2013), and Heliyon (Elsevier). He also has served as Session Chair of the Biomedical Engineering Society (BMES) Annual Meeting since 2013. He also has served as study section member for the National Institute of Health (NIH) and panel member of the National Science Foundation (NSF). Dr. Wang will continue to employ his multidisciplinary expertise in the areas of materials science, stem cells, microfabrication, and pharmaceutical chemistry to address and resolve challenging problems of human health.